The FDA has approved Regeneron and Sanofi’s Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis, making it the first drug approved for this indication.
If you are not happy with the results below please do another search
50 search results for:
Ordaōs and NonExomics announced a research pact to develop mini-proteins, called miniPROs, for three specific difficult-to-target rare cancers.
Elevation Oncology, Janssen, Merck and Teclison discuss the latest innovations in immuno-oncology.
Siga Technologies has won a new contract for its oral antiviral drug, Tpoxx, worth up to $10.7 million from the U.S. Department of Defense as the country stocks up on the treatment amid a monkeypox outbreak.
Biohaven Pharmaceutical Holding Company Ltd said its experimental drug to treat amyotrophic lateral sclerosis (ALS) failed a clinical study, the second therapy by the drugmaker to fail trials in recent months.
The company is touting the platform as the first fully digital clinical trial solution for oncology, hematology, and urology.
A federal judge in New York has frozen the assets of dozens of people and entities accused of operating a massive nationwide scheme to distribute counterfeit bottles of Gilead Sciences Inc. HIV drugs, including two alleged “kingpins.”
The drugmaker said in a statement that it reached a cooperation framework agreement with Sinopharm that grants the Chinese company distribution and exclusive import rights of the medicine in the China mainland market.
Medical science liaisons (MSLs) play an essential and prominent role in the pharmaceutical industry. To support the various market changes, the scope of the average MSL function will expand. This article explores the evolving role of MSLs and their value for biopharmaceutical companies, and examines how best to utilize their expertise.
Funding initiatives this week saw money flow into cancer, rare liver diseases, respiratory depression, chemotherapy-related toxicities and a cutting-edge machine learning platform, while a biotech start-up guns for an IPO.